Archives: Agenda

• ISR Market Research results and insights into the State of AI in Clinical Trials
• Opportunities for companies that embrace AI across the Clinical Trial Lifecycle
• Adoption of AI in MedTech for Clinical Product Development

• Align protocol design with MDR, FDA and global regulatory expectations
• Manage endpoint variability across geographies without undermining quality
• Avoid costly rework by building flexibility into trial strategy

• The reality of PMCF under EU MDR: mandatory, continuous and increasingly scrutinised
• Common pitfalls in current PMCF strategies and why many approaches no longer satisfy Notified Body expectations
• Introducing 1Survey+, a clinical-grade, regulator-ready PMCF platform designed in accordance with ISO 14155
• From fragmented PMCF activities to portfolio-level standardisation and scalability

Senior representative, Behavox

Step into the Future of AI from pioneering intelligent automation to unleashing the power of Agentic AI across the SS&C estate. Join us on our journey, where we are moving beyond automation to build AI agents that are driving change at scale with a digital-first mindset and governance-first approach. Walk away inspired, informed, and ready to lead your own transformation.

What you’ll take away:
• The story of our evolution—from automation to AI-led operations.
• How we’ve deployed agentic AI agents at scale, with governance at the core.
• Why experience, innovation, and trust matter when choosing your AI partner.

Financial institutions are under pressure to innovate with AI and advanced analytics, yet most still struggle with fragmented data estates. Explore how leading financial institutions are utilising technology to create a dynamic, automated map from mainframes to the cloud that shows exactly how data moves and transforms. Learn how this end-to-end intelligence allows organisations to prove compliance instantly and align teams around a single source of truth unifying governance, accelerating AI and enabling confident decision making

Generative AI is no longer novel. Financial institutions are now at a crossroads: either continue managing a fleet of helpful “assistants” or transition to Autonomous Agents. While basic LLMs can summarise data, true “Agents with Agency” can execute complex workflows – from AML investigations to KYB verification – autonomously. However, in the high-stakes world of FSI, there remains a significant risk. We will deconstruct a manual Anti-Money Laundering (AML) workflow to show how agentic systems mimic human reasoning, and more importantly, how adopting a governance layer ensures these agents operate within safe, auditable parameters, to move beyond the “AI as a toy” narrative and explore the architectural shift required to give AI the power to act.

Hyper-personalisation is already a strategic priority for most wealth managers. The barrier isn’t ambition or data; it’s the operational layer sitting between advisor intent and client experience. Every personalised touchpoint depends on a workflow: onboarding, review triggers, threshold alerts, life event responses. When those workflows are batch-driven or generic, personalisation fails silently, and clients notice. When those workflows are manual interactions can be truly personal but fail to scale. This session explores how wealth management can close the gap between personalisation strategy and delivery reality